Athersys, Inc. (ATHX)

Market Cap	25.56M
Revenue (ttm)	6.02M
Net Income (ttm)	-81.24M
Shares Out	17.21M
EPS (ttm)	-7.90
PE Ratio	n/a
Forward PE	0.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	103,768
Open	1.56
Previous Close	1.51
Day's Range	1.44 - 1.56
52-Week Range	0.50 - 33.25
Beta	-0.95
Analysts	Sell
Price Target	3.06 (+112.5%)
Earnings Date	Mar 21, 2023

About ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 104
• Stock Exchange: NASDAQ
• Ticker Symbol: ATHX

Financial Performance

In 2021, Athersys's revenue was $5.51 million, an increase of 282.92% compared to the previous year's $1.44 million. Losses were -$86.96 million, 10.4% more than in 2020.

Analyst Forecast

According to 6 analysts, the average rating for ATHX stock is "Sell." The 12-month stock price forecast is $3.06, which is an increase of 112.50% from the latest price.

Price Target

$3.06

(112.50% upside)

Analyst Consensus: Sell